Clinical Trial Update: Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema [Phase 1]

View source ↗

Summary

A Phase 1 safety trial of intravitreal EBI-031 for diabetic macular edema was withdrawn, including single and repeat injection cohorts.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• EBI-031

Snippet

Sponsor: Eleven Biotherapeutics | Conditions: Diabetic Macular Edema | Phase 1 | Status: WITHDRAWN